




PHARMACEUTICAL 2020

Evelo Biosciences Inc.
Rank 221 of 358





PHARMACEUTICAL 2020

Evelo Biosciences Inc.
Rank 221 of 358

The relative strengths and weaknesses of Evelo Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evelo Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Evelo Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 30%, being 6.6% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	81,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,743
Liabilities, Non-Current	19,832
Other Assets	1,570
Other Compr. Net Income	18
Other Expenses	190
Other Liabilities	1,148
Other Net Income	1,075
Other Revenues	0
Property and Equipment	8,341
Research and Development	63,128
Selling, General and Administrative Expense	23,229

Output Variable	Value in 1000 USD
Assets	90,920
Liabilities	30,723
Expenses	86,547
Revenues	0
Stockholders Equity	60,197
Net Income	-85,472
Comprehensive Net Income	-85,463
Economic Capital Ratio	30%